Suppr超能文献

骨髓增生异常综合征中骨髓基质细胞的内在生长缺陷。

Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes.

机构信息

Laboratoire d'Hématologie, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne Cedex, France.

出版信息

Stem Cells Dev. 2012 Jul 1;21(10):1604-15. doi: 10.1089/scd.2011.0390. Epub 2011 Oct 27.

Abstract

Myelodysplastic syndromes (MDSs) are clonal disorders of hematopoietic stem cells (HSCs) characterized by ineffective hematopoiesis. MDSs are responsible for 1 or several peripheral cytopenias. The evidence accumulated in recent years demonstrates that in addition to HSC defects, a particular role is also played by stromal microenvironment dysfunctions, which mediate the direct contact with hematopoietic precursor cells (HPCs). These interactions help regulate different adhesion-related processes, such as progenitor cell proliferation, apoptosis, clonogenic growth, and maintenance in in vitro cultures. As previously reported, these interactions are responsible for altering the microenvironment in MDS. Herein, we present a novel selection protocol for obtaining a standards-compliant mesenchymal stromal cell (MSC) preparation. This method allowed us to comparatively analyze 2 subpopulations of bone marrow MSCs (BM-MSCs) in terms of their adhesion profiles and growth abilities: BM-MSCs selected from MDS settings and their normal counterparts. Functional assays revealed that the MSCs from MDS are intrinsically pathological, thus showing a continuous decline of proliferation and a reduced clonogenic capacity during 14 days of culture and in the absence of signals from hematopoietic cells. The MSC growth defects were significantly correlated with decreases in CD44 adhesion molecules and CD49e (α5-integrin).

摘要

骨髓增生异常综合征(MDS)是造血干细胞(HSCs)的克隆性疾病,其特征为无效造血。MDS 可导致 1 种或多种外周血细胞减少。近年来积累的证据表明,除了 HSC 缺陷外,基质微环境功能障碍也起着特殊作用,其介导与造血前体细胞(HPCs)的直接接触。这些相互作用有助于调节不同的与黏附相关的过程,如祖细胞的增殖、凋亡、集落生成和体外培养中的维持。如前所述,这些相互作用负责改变 MDS 中的微环境。在此,我们提出了一种新的选择方案,用于获得符合标准的间充质基质细胞(MSC)制剂。该方法允许我们比较分析 MDS 环境中分离的骨髓间充质干细胞(BM-MSCs)和其正常对应物的黏附谱和生长能力:从 MDS 患者中分离的 BM-MSCs 和其正常对照者。功能分析显示,MDS 来源的 MSC 具有内在的病理特性,因此在 14 天的培养过程中,在没有造血细胞信号的情况下,其增殖持续下降,集落生成能力降低。MSC 的生长缺陷与 CD44 黏附分子和 CD49e(α5 整合素)的减少显著相关。

相似文献

1
Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes.
Stem Cells Dev. 2012 Jul 1;21(10):1604-15. doi: 10.1089/scd.2011.0390. Epub 2011 Oct 27.
2
Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.
Stem Cells Dev. 2014 May 15;23(10):1109-20. doi: 10.1089/scd.2013.0441. Epub 2014 Feb 18.
7
Primary mesenchymal stem and progenitor cells from bone marrow lack expression of CD44 protein.
J Biol Chem. 2012 Jul 27;287(31):25795-807. doi: 10.1074/jbc.M112.339622. Epub 2012 May 31.
9
Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization.
Leuk Res. 2005 Feb;29(2):215-24. doi: 10.1016/j.leukres.2004.06.011.
10
Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes.
Cancer Lett. 2012 Apr 28;317(2):136-43. doi: 10.1016/j.canlet.2011.08.030. Epub 2011 Oct 15.

引用本文的文献

1
Mesenchymal Stem Cells in Myelodysplastic Syndromes and Leukaemia.
Biomedicines. 2024 Jul 26;12(8):1677. doi: 10.3390/biomedicines12081677.
2
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Hemasphere. 2024 May 15;8(5):e64. doi: 10.1002/hem3.64. eCollection 2024 May.
3
Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities.
Heliyon. 2024 Jan 22;10(3):e25081. doi: 10.1016/j.heliyon.2024.e25081. eCollection 2024 Feb 15.
5
Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells.
Mediterr J Hematol Infect Dis. 2023 Sep 1;15(1):e2023055. doi: 10.4084/MJHID.2023.055. eCollection 2023.
7
Mesenchymal stromal cell senescence in haematological malignancies.
Cancer Metastasis Rev. 2023 Mar;42(1):277-296. doi: 10.1007/s10555-022-10069-9. Epub 2023 Jan 9.
9
Bone marrow niches in myelodysplastic syndromes.
J Cancer Metastasis Treat. 2021;7. doi: 10.20517/2394-4722.2021.120. Epub 2021 Jul 14.

本文引用的文献

1
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.
J Clin Invest. 2011 Jun;121(6):2371-82. doi: 10.1172/JCI45559. Epub 2011 May 2.
2
Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging.
Stem Cells Dev. 2011 Jan;20(1):53-66. doi: 10.1089/scd.2010.0040. Epub 2010 Oct 26.
4
Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate.
Biomaterials. 2010 Jan;31(2):270-8. doi: 10.1016/j.biomaterials.2009.09.043. Epub 2009 Sep 26.
6
Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms.
Mol Ther. 2009 Jun;17(6):939-46. doi: 10.1038/mt.2009.62. Epub 2009 Mar 31.
8
Physiological roles for ecto-5'-nucleotidase (CD73).
Purinergic Signal. 2006 Jun;2(2):351-60. doi: 10.1007/s11302-005-5302-5. Epub 2006 Jun 1.
10
Adhesion of human hematopoietic progenitor cells to mesenchymal stromal cells involves CD44.
Cells Tissues Organs. 2008;188(1-2):160-9. doi: 10.1159/000112821. Epub 2007 Dec 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验